Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Diagnostic Investigation of Sudden Cardiac Event Risk

Study:

n/a

Rationale:

n/a

Purpose:

Heart failure (HF) affects 5 million Americans, with 500,000 new cases diagnosed and 250,000 deaths each year. The two major causes of morbidity and mortality in HF are pump failure and sudden, lethal ventricular arrhythmias, the latter of which accounts for 40-50% of HF deaths. Arrhythmias may be precipitated by a complex interaction of genetic and environmental factors. Establishing increased risk for arrhythmias before a severe life-threatening event is critically important. However, this remains a significant medical challenge. Several genetic mutations associated with rare, inherited arrhythmia disorders have been identified. The aim of this study is to identify novel genetic and other biological markers that distinguish patients at increased risk for lethal ventricular arrhythmias in a broader population.

Study Status: Suspended

Recruiting:
n/a

Condition Intervention Phase
Arrhythmia n/a N/A

Verified by CardioDx October, 2011

Sponsored by: CardioDx
Information provided by: CardioDx
ClinicalTrials.gov identifier: NCT00500708

Study Type: Interventional

Study Design: Observational Model: Cohort, Time Perspective: Prospective

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.